Concepedia

Kari Guthrie

KG

Statistics

Publications

4

Citations

256

H-Index

4

Active since

2011

Affiliations

University of Colorado Denver(Current)

Array BioPharma (United States)

The University of Texas MD Anderson Cancer Center

BC Cancer Agency

Kari Guthrie is an author at University of Colorado Denver specializing in pharmacokinetics of anticancer agents, pharmacokinetics of anticancer drugs, and oncology pharmacology.

Publications per year

2011–2017

4

Publications

4

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)

Stacy L. Moulder, Virginia F. Borges, Tara Baetz et al. · Clinical Cancer Research · 2017 · 160 citations

, , +16

A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

Richard S. Finn, Milind Javle, Benjamin Tan et al. · Journal of Clinical Oncology · 2012 · 50 citations

, , +16

Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.

Johanna C. Bendell, Kyriakos P. Papadopoulos, Suzanne F. Jones et al. · Molecular Cancer Therapeutics · 2011 · 28 citations

, , +15

Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.

Stacy L. Moulder, Tara Baetz, Virginia F. Borges et al. · Molecular Cancer Therapeutics · 2011 · 18 citations

, , +17

1–4 of 4